Biogen Inc.
NASDAQ:BIIB
Overview | Financials
Company Name | Biogen Inc. |
Symbol | BIIB |
Currency | USD |
Price | 165.79 |
Market Cap | 24,158,753,010 |
Dividend Yield | 0% |
52-week-range | 165.53 - 268.3 |
Industry | Drug Manufacturers—General |
Sector | Healthcare |
CEO | Mr. Christopher A. Viehbacher |
Website | https://www.biogen.com |
An error occurred while fetching data.
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD